Field Maturity
Where this space sits on the nascent-to-established spectrum, and the signals that place it there.
Based on the linked trials and publications, radioligand therapy for prostate cancer appears to be at TRL 7-8 - a field with demonstrated clinical efficacy, regulatory approvals in hand, and an extensive late-stage trial infrastructure. The sample of 500 trials includes 43 Phase 3 trials and 187 Phase 2 trials within the 378 phase-labeled trials (the phased subset of 465 interventional), alongside 646 peer-reviewed-dominant publications and NIH-linked funding of $105.9M across 115 projects, collectively pointing to a technology that has moved well beyond proof-of-concept and is operating in the realm of clinical optimization, combination strategies, and real-world deployment. A researcher entering this space now is joining a field that is refining rather than discovering - the core mechanism is validated, the competitive intensity is high, and incremental differentiation rather than platform novelty is the dominant mode of scientific work.
Evidence43 Phase 3 trials, 187 Phase 2 trials, 148 Phase 1 trials across 500 total linked trials; 646 linked publications with 6% preprint ratio; $105.9M NIH-linked funding across 115 projects; 29 linked patents
With 646 linked publications, the 6% preprint ratio (approximately 40 preprints) is interpretable as a meaningful signal at this sample size - the low preprint share is consistent with a mature, peer-review-dominant field where findings are sufficiently established to clear editorial gatekeeping rather than requiring rapid early dissemination, though it does not rule out active emerging sub-niches within the broader topic.
Evidence646 total linked publications, 40 preprints (~6% preprint ratio)
The trial phase distribution across 500 linked trials - 148 Phase 1, 187 Phase 2, and 43 Phase 3, within 378 phase-labeled trials (the phased subset of 465 interventional) - reflects a field with substantial late-stage clinical activity; the relatively modest Phase 3 count relative to Phase 2 suggests ongoing maturation rather than full saturation, and the 138 randomized trials and 26 with double-blinded or higher masking out of 500 total reflect moderate statistical rigor, with 264 trials carrying a Data Monitoring Committee indicating broad infrastructure investment. Of 500 trials, 138 are RANDOMIZED and 26 carry DOUBLE-blinded or higher masking; 264 have an explicit Data Monitoring Committee. Statistical rigor is Medium - present at scale for randomization and DMC oversight, but blinding remains limited, which is expected given the nature of radioligand administration.
Evidence500 total trials; 148 Phase 1, 187 Phase 2, 43 Phase 3 among 378 phase-labeled trials; 465 interventional, 35 observational; 138 randomized, 26 double-blinded or higher, 264 with DMC
The linked patent sample contains 29 patents with 0 filed in the last two years (0% recency ratio); while 29 patents is a sufficient count to note the directional signal, the zero recent filings may reflect a field where foundational IP was secured earlier and current competitive activity has shifted toward clinical and regulatory execution rather than novel IP generation, though NIH-linked patent databases may not capture all proprietary filings and this recency signal should be interpreted with caution.
Evidence29 linked patents, 0 in last 2 years, 0% recency ratio
For a researcher, the density of Phase 2 activity (187 trials) relative to Phase 3 (43 trials) within 500 linked trials suggests that combination therapy regimens, patient selection biomarkers, and dosimetry optimization represent the highest-value investigator-initiated niches - these are areas where R01 and R21 mechanisms anchored in mechanistic or translational questions can complement, rather than duplicate, industry-led efficacy trials. NIH-linked funding ran from $40.9M in FY2024 to $51.2M in FY2025 in this sample, though two data points do not establish a trend, and the therapeutics category dominates within the 115 linked projects; a researcher seeking differentiation may find more proposal space in dosimetry science, resistance mechanisms, or combination sequencing rather than head-to-head efficacy, where 43 Phase 3 trials already occupy much of the evidentiary ground. Collaborator targeting should prioritize nuclear medicine physicists, radiation biologists, and biomarker-focused translational teams, given that the 26 double-blinded trials out of 500 and 138 randomized trials indicate that rigorously designed sub-studies embedded within existing platform trials may be more fundable than standalone RCTs in this competitive environment.
Evidence500 total trials; 43 Phase 3, 187 Phase 2, 148 Phase 1 among 378 phase-labeled trials (phased subset of 465 interventional); 115 NIH-linked projects; $40.9M FY2024, $51.2M FY2025 (two data points only); 138 randomized, 26 double-blinded or higher